Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE Trial
Clinical Lung Cancer · 2024
DOI: 10.1016/j.cllc.2024.01.009 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Taichi Matsubara und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Atezolizumab following platinum chemotherapy and complete pulmonary resection has become the new standard of adjuvant care for patients with stage II-III non-small cell lung cancer (NSCLC) expressing programmed death-ligand 1 (PD-L1). However, the efficacy and safety of postoperative adjuvant therapy and subsequent atezolizumab in patients aged 75 and older have not been established. METHODS: Patients with completely resected stage II-III NSCLC aged 75 and older will be prospectively registered in this single-arm phase II study. The enrolled patients will receive cisplatin plus vinorelbine (CDDP + VNR) followed by atezolizumab for up to 12 months. PD-L1 expression in at least 1% of cells will be confirmed by immunohistochemical staining. We plan to enroll 33 patients over 1 year at 25 institutions in Japan. The primary endpoint is the completion rate of adjuvant treatment (CDDP + VNR initiation to atezolizumab completion). CONCLUSION: The present study represents the first prospective trial of the tolerability of postoperative adjuvant therapy with immune checkpoint inhibitors in elderly individuals. The results of this trial might help promote postoperative adjuvant immunotherapy in the future for the elderly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan.
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. Electronic address: masafumiyamaguchi@yahoo.co.jp.
- Department of Biostatistics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.
- Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Zitieren
APA
Matsubara, T., Yamaguchi, M., Shimokawa, M., & Okamoto, I. (2024). Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE Trial. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.01.009
Vancouver
Matsubara T, Yamaguchi M, Shimokawa M, Okamoto I. Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE Trial. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.01.009
BibTeX
@article{Matsubara2024,
author = {Matsubara, Taichi and Yamaguchi, Masafumi and Shimokawa, Mototsugu and Okamoto, Isamu},
title = {Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE Trial},
journal = {Clinical Lung Cancer},
year = {2024},
doi = {10.1016/j.cllc.2024.01.009}
}
EUVIMED